Identification of ins(8;21) with AML1/ETO fusion in acute myelogenous leukemia M2 by molecular cytogenetics

被引:10
作者
Urioste, M [1 ]
Martínez-Ramírez, A
Cigudosa, JC
Mateo, MS
Martínez, P
Contra, T
Benítez, J
机构
[1] Inst Salud Carlos III, Ctr Nacl Invest Oncol, Dept Genet Humana, Programa Patol Mol, Madrid, Spain
[2] Hosp Nacl Paraplej, Genet Lab, Toledo, Spain
[3] Hosp Nino Jesus, Dept Oncol, Madrid, Spain
关键词
D O I
10.1016/S0165-4608(01)00555-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A high percentage of cases of acute myelogenous leukemia (AML) of the M2 subtype show a rearrangement between the AML1 and ETO genes. The detection of the AMLI/ETO fusion has clinical relevance because patients with this subtype have a good prognosis. We present the results of conventional and molecular cytogenetic studies in a patient with acute myelogenous leukemia French-American-British M2 classification, who had a complex karyotype involving chromosomes 8 and 21. Dual-color fluorescence in situ hybridization (FISH) using the AMLI/ETO probe demonstrated a recombination of both genes on an add(8) chromosome. The use of other FISH probes (CEP8, c-myc and TEL21) and spectral karyotyping indicated that AML1/ETO fusion occurred as a consequence of a previously undescribed ins(8;21)(q22; q22.1q22.3). (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:83 / 86
页数:4
相关论文
共 19 条
[1]  
BERNHEIM A, 1990, CANCER GENET CYTOGEN, V44, P169
[2]  
DOWNING JR, 1993, BLOOD, V81, P2860
[3]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[4]   Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations [J].
Harrison, CJ ;
Radford-Weiss, I ;
Ross, F ;
Rack, K ;
le Guyader, G ;
Vekemans, M ;
Macintyre, E .
CANCER GENETICS AND CYTOGENETICS, 1999, 112 (01) :15-20
[5]  
HEIM S, 1995, CANC CYTOGENETICS CH, P88
[6]  
Kazama H, 1996, Rinsho Ketsueki, V37, P1297
[7]   Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials [J].
Langabeer, SE ;
Walker, H ;
Rogers, JR ;
Burnett, AK ;
Wheatley, K ;
Swirsky, D ;
Goldstone, AH ;
Linch, DC .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :925-928
[8]   Identification of chromosome changes in acute myeloid leukemia (AML-M2) by molecular cytogenetics [J].
LaStarza, R ;
Matteucci, C ;
Crescenzi, B ;
Perla, G ;
Carotenuto, M ;
Martelli, MF ;
Hagemeijer, A ;
Mecucci, C .
CANCER GENETICS AND CYTOGENETICS, 1997, 95 (02) :148-152
[9]  
Mitelman F., 1995, ISCN 1995 INT SYSTEM
[10]  
Mitelman F., MITELMAN DATABASE CH